The Effect of Dual Task Training on Cognitive in Alzheimer's Disease
NCT07163039, Not applicable, Not yet recruiting, Fenerbahce University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | The Effect of Dual Task Training on Cognitive in Alzheimer's Disease | ClinicalTrials.gov |
| NCT number | NCT07163039 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Fenerbahce University | ClinicalTrials.gov |
| Conditions | Alzheimer Disease | ClinicalTrials.gov |
| Interventions | Dual-Task Motor-Cognitive Training, Conventional Exercise Training | ClinicalTrials.gov |
| First posted | 2025-09-09 | ClinicalTrials.gov |
| Last updated | 2025-09-09 | ClinicalTrials.gov |
Registered outcomes 18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | d2 Test of Attention | From enrollment to the end of treatment at 8 weeks | A widely used neuropsychological test evaluating visual attention and processing speed. Participants are asked to quickly and accurately mark target symbols (e.g., the letter "d" with two dashes) among distractors on a sheet consisting of similar letters and symbols. | ClinicalTrials.gov |
| Primary | Trail Making Test Part A (TMT-A) | From enrollment to the end of treatment at 8 weeks | Assesses visual attention, processing speed, and psychological flexibility. The participant is required to connect numbered circles from 1 to 25 in order as quickly as possible. | ClinicalTrials.gov |
| Primary | Stroop Test | From enrollment to the end of treatment at 8 weeks | Stroop Test: Evaluates executive functions and attentional control. The participant must state the ink color of a word rather than reading the written word itself (e.g., the word "Blue" written in red ink should be answered as "red") | ClinicalTrials.gov |
| Primary | Trail Making Test Part B (TMT-B): | From enrollment to the end of treatment at 8 weeks | Trail Making Test Part B (TMT-B): Used to assess executive functions, cognitive flexibility, and attention. The participant alternates between numbers and letters in sequence (1-A-2-B-3-C…) | ClinicalTrials.gov |
| Primary | Montreal Cognitive Assessment (MoCA) | From enrollment to the end of treatment at 8 weeks | Montreal Cognitive Assessment (MoCA): Evaluates memory, attention, executive functions, and visuospatial skills. It is a standard and validated tool for monitoring cognitive status and comparing pre- and post-intervention performance in Alzheimer's patients | ClinicalTrials.gov |
| Secondary | Symbol Digit Modalities Test (SDMT) | From enrollment to the end of treatment at 8 weeks | Symbol Digit Modalities Test (SDMT): Measures processing speed and attention. Participants are presented with a key of symbol-digit pairings and asked to match as many symbols with their corresponding digits as possible within a set time | ClinicalTrials.gov |
| Secondary | Functional Near-Infrared Spectroscopy (fNIRS) | From enrollment to the end of treatment at 8 weeks | Functional Near-Infrared Spectroscopy (fNIRS): A non-invasive method to measure prefrontal cortex activation by monitoring oxygenated and deoxygenated hemoglobin levels | ClinicalTrials.gov |
| Secondary | Disability Assessment for Dementia (DAD) | From enrollment to the end of treatment at 8 weeks | Disability Assessment for Dementia (DAD): Developed to assess independence in activities of daily living among individuals with dementia. It evaluates both basic and instrumental activities of daily living, including self-care and social functioning | ClinicalTrials.gov |
| Secondary | Dual Task Protocol | From enrollment to the end of treatment at 8 weeks | Dual Task Protocol: Participants will perform physical and cognitive tasks simultaneously. For example, during walking, they will be asked to complete word generation, simple arithmetic, or other attention-demanding tasks | ClinicalTrials.gov |
| Secondary | Performance Measures: Walking speed | From enrollment to the end of treatment at 8 weeks | Walking speed (measured using a metronome or gait analysis system). | ClinicalTrials.gov |
| Secondary | Performance Measures: Step count | From enrollment to the end of treatment at 8 weeks | Step count (measured using a metronome or gait analysis system). | ClinicalTrials.gov |
| Secondary | Performance Measures: Number of correct response Number of correct responses | From enrollment to the end of treatment at 8 weeks | Number of correct responses recorded during the secondary cognitive task. | ClinicalTrials.gov |
| Secondary | Performance Measures: incorrect response | From enrollment to the end of treatment at 8 weeks | Percentage of incorrect responses recorded during the secondary cognitive task. | ClinicalTrials.gov |
| Secondary | Gait Analysis System: Walking speed during single-task walking | From enrollment to the end of treatment at 8 weeks | Provides objective evaluation of walking dynamics using pressure sensors, motion capture systems, or accelerometers. | ClinicalTrials.gov |
| Secondary | Gait Analysis System: Step length during single-task walking | From enrollment to the end of treatment at 8 weeks | Provides objective evaluation of walking dynamics using pressure sensors, motion capture systems, or accelerometers. | ClinicalTrials.gov |
| Secondary | Gait Analysis System:Balance during dual-task walking | From enrollment to the end of treatment at 8 weeks | Provides objective evaluation of walking dynamics using pressure sensors, motion capture systems, or accelerometers. | ClinicalTrials.gov |
| Secondary | Gait Analysis System: Postural control during dual-task walking | From enrollment to the end of treatment at 8 weeks | Provides objective evaluation of walking dynamics using pressure sensors, motion capture systems, or accelerometers. | ClinicalTrials.gov |
| Secondary | Electromyography (EMG) | From enrollment to the end of treatment at 8 weeks | Electromyography (EMG): Measures muscle electrical activity through surface electrodes, providing data on contraction duration, activation levels, and coordination (De Luca, 1997). EMG will be used to assess changes in motor control and muscle activation during dual-task training. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Cancellation Test | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)